Drugs / 89Zr-DFO-AP-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05974579 | Nov 2023 → Dec 2024 | amyotrophic lateral sclerosis | University of Sherbrooke | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-AP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05974579 ↗ |
| Known as | [89Zr]Zr-DFO-AP-101 | “A phase I study to evaluate the dosimetry and safety of [(89)Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis.” PMID 41872337 ↗ Mar 20261“The primary goal of this phase I study is evaluating the safety and biodistribution of the new tracer \[89Zr\]Zr-DFO-AP-101 in healthy volunteers and ALS patients.” NCT05974579 ↗ |
| Route | Intravenous | “a single intravenous dose” NCT05974579 ↗ |
| Target | SOD1 | “targeting mSOD1” PMID 41872337 ↗ Mar 2026 |